SCHEMBL26409406

SCHEMBL26409406

Cn1ccc2cc(O)c(O)cc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 3/20 0.49
BRD9 Q9H8M2 2/20 0.42
BRD4 O60885 1/20 0.42
TAF1 P21675 1/20 0.42
BRPF1 P55201 1/20 0.42
CREBBP Q92793 1/20 0.42
CECR2 Q9BXF3 1/20 0.42
DAO P14920 1/20 0.41
KDM4E B2RXH2 1/20 0.37
KDM6A O15550 1/20 0.37
KDM4A O75164 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KDM5C P41229 1/20 0.37
KDM2B Q8NHM5 1/20 0.37
DOHH Q9BU89 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37
GAA P10253 1/20 0.37
SRC P12931 2/20 0.36
MIF P14174 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30186388 0.86 BRD9 (0.41) TNFBRD9BRD4TAF1BRPF1
SCHEMBL28928364 0.86 BRD9 (0.41) TNFBRD9BRD4TAF1BRPF1
SCHEMBL13007272 0.83 TNF (0.40) TNFBRD9BRD4TAF1BRPF1
SCHEMBL3768022 0.83 TNF (0.46) TNFKDM4ECYP2C9GAAHPGD
SCHEMBL3770428 0.83 TNF (0.46) TNFKDM4ECYP2C9GAAHPGD
SCHEMBL13007276 0.83 TNF (0.40) TNFBRD9BRD4TAF1BRPF1
SCHEMBL29377689 0.79 CDK4 (0.41) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL22129340 0.79 CDK4 (0.41) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL1239205 0.79 CDK4 (0.41) BRD9BRD4TAF1BRPF1CREBBP
SCHEMBL30617770 0.77 BRD4 (0.42) BRD9BRD4TAF1BRPF1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374005-A1 LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS FEDORA PHARMACEUTICALS INC. (CA) 2023-11-23 US disclosed
US-11780832-B2 Lactivicin compounds, their preparation and use as antibacterial agents FEDORA PHARMACEUTICALS INC. (CA) 2023-10-10 US disclosed
US-11780832-B2 Lactivicin compounds, their preparation and use as antibacterial agents FEDORA PHARMACEUTICALS INC. (CA) 2023-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374005-A1 LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS LCT, VIP, LPO TNF 948/4885BRD9 4206/4885BRD4 4596/4885
US-11780832-B2 Lactivicin compounds, their preparation and use as antibacterial agents LCT, VIP, LPO TNF 925/4885BRD9 4200/4885BRD4 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.